Updated Covid Vaccines Significantly Cut Risk of Heart Attacks and Strokes, Massive VA Study Finds

For years, the medical community has understood that SARS-CoV-2 is not merely a respiratory pathogen, but a vascular one capable of wreaking havoc on the heart and blood vessels. Now, a massive new study provides compelling evidence that updating immunity against the virus does far more than prevent a cough or a fever. According to research published in JAMA Internal Medicine, the 2024–2025 Covid-19 vaccines significantly lowered the risk of major adverse cardiovascular events, including heart attacks, strokes, and heart failure.[1][3]

The findings emerge from a sweeping analysis of electronic medical records from the Department of Veterans Affairs. Researchers tracked 1,039,659 patients within the VA's St. Louis Health Care System who received a seasonal flu shot between September and December 2024. Roughly a third of those patients opted to receive the updated Covid-19 vaccine at the same time, while the remaining two-thirds received only the flu shot, serving as a massive, real-world control group.[2][4]

Over the following eight months, the data revealed a stark divergence in cardiovascular outcomes. The group that received the updated Covid-19 vaccine experienced a nearly 38 percent reduction in Covid-associated major adverse cardiovascular events, commonly referred to as MACE. This composite metric encompasses cardiovascular death, acute myocardial infarction, stroke, and hospitalization for heart failure.[1][4]

When researchers broke down the specific endpoints, the protective effects were even more pronounced. The updated vaccines proved nearly 58 percent effective at preventing Covid-associated cardiovascular death. They were also 38.5 percent effective against Covid-associated heart attacks and roughly 42 percent effective at preventing hospitalizations for heart failure. These figures demonstrate a robust defense mechanism operating well beyond the lungs.[2][3]

The demographic breakdown of the study highlights exactly who stands to gain the most from this protection. The cardiovascular benefits skewed heavily toward the most vulnerable populations, with the strongest effects seen in patients aged 75 and older. In this older cohort, vaccine effectiveness against Covid-associated MACE jumped to nearly 51 percent, cementing the shot's role as a critical intervention for geriatric care.[2][6]

While the relative risk reduction is striking, clinical experts are quick to contextualize the absolute numbers. Because cardiovascular emergencies triggered directly by a documented Covid-19 infection are relatively rare in the broad population, the absolute benefit appears modest on paper. The study estimated that the vaccines dropped the rate of Covid-associated MACE from about 5 in 10,000 patients to 3 in 10,000. However, extrapolated across a population of hundreds of millions, that subtle shift translates to thousands of lives saved and hospitalizations averted.[4][6]

Perhaps the most surprising revelation in the JAMA study was a secondary finding that caught even the researchers off guard. The data showed that Covid vaccination was tied to a nearly 24 percent reduction in all-cause cardiac events. This means the vaccinated cohort experienced significantly fewer heart attacks and strokes overall, regardless of whether they ever had a documented, formal diagnosis of Covid-19 during the study window.[1][5]

This unexpected all-cause benefit points to a fascinating biological mechanism. Medical researchers hypothesize that the vaccines are likely preventing silent, asymptomatic, or subclinical Covid-19 infections from taking root. Even when a patient feels fine and never takes a test, a mild SARS-CoV-2 infection can trigger systemic inflammation and endothelial dysfunction—a condition where the inner lining of blood vessels fails to perform normally.[5][6]

Endothelial dysfunction is a known precursor to the blood-clotting cascades that cause ischemic strokes and myocardial infarctions. By neutralizing the virus before it can provoke this inflammatory response, the vaccine effectively acts as a cardiovascular shield. It dampens the systemic stress that often pushes a vulnerable, plaque-lined artery over the edge into a full-blown cardiac emergency.[3][6]

These findings do not exist in a vacuum; they build upon a growing mountain of international evidence linking Covid-19 immunity to heart health. A 2024 study analyzing 46 million adults in England similarly found that the incidence of arterial and venous thrombotic events plummeted following vaccination. That UK study noted that the risk of heart attacks and strokes was lowest in the immediate weeks following a dose, reinforcing the immediate vascular benefits of the shot.[4]

The VA study also arrives alongside corroborating data regarding the general efficacy of the 2024–2025 vaccine formulations. A separate CDC analysis found the updated shots were 41 percent effective against critical illness and 35 percent effective against hospitalization in adults. Meanwhile, a European study published in JAMA Network Open demonstrated a 59 percent effectiveness against symptomatic disease in older adults, proving the updated formulas remain highly capable despite the virus's continuous mutations.[2][5]

Naturally, discussions of vaccines and heart health often surface concerns about myocarditis, a rare inflammation of the heart muscle previously linked to mRNA vaccines. While earlier studies did detect a slight, transient increase in myocarditis risk following certain doses, researchers emphasize that the risk of severe cardiac complications from an actual Covid-19 infection is exponentially higher. The massive reduction in heart attacks and strokes vastly outweighs the rare safety signals, particularly for older adults.[3][4]

For practicing clinicians and public health officials, the VA data offers a powerful new narrative to combat vaccine fatigue. As the general public increasingly treats Covid-19 as a routine seasonal nuisance, uptake of the updated shots has lagged. By reframing the vaccine as a proven method of secondary cardiovascular prevention, doctors have a tangible, high-stakes metric to present to their patients.[2][6]

Ultimately, the research underscores a profound shift in how the medical community views pandemic-era interventions. What began as an emergency measure to keep patients off ventilators has evolved into a sophisticated tool for managing long-term vascular health. For millions of older adults navigating hypertension, diabetes, and heart disease, the annual Covid-19 shot is proving to be as vital to their heart as it is to their lungs.[1][3]